IRVINE, Calif. - Biomerica, Inc. (NASDAQ:BMRA), a diagnostic solutions provider with a market capitalization of $6.4 million and showing a notable 16.6% year-to-date stock return, has received ...
This test, which delivers results in 10 minutes from a simple finger-prick blood sample, is designed to detect early signs of prostate cancer by measuring elevated PSA levels. The approval marks a ...
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer: Irvine, California Saturday, January 18, 2025, 14:00 Hrs [IST] Bio ...
(Nasdaq: BMRA), a global provider of innovative diagnostic solutions, is proud to announce that its Fortel ® Prostate Specific Antigen (PSA) Screening Test has received approval from the United ...